The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Forbes6/17/2026Neutral
ANTX
AN2 Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$158.83M
P/E Ratio
—
EPS
$-1.10
Beta
-0.99
52W High
$6.91
52W Low
$1.00
50-Day MA
$4.60
200-Day MA
$2.50
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About AN2 Therapeutics Inc
Anthem, Inc., is a health benefits company in the United States. The company is headquartered in Indianapolis, Indiana.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -44.60% |
| Return on Assets | -27.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.27 |
| Price-to-Book | 1.95 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $36.02M |
| Float | $20.01M |
| % Insiders | 18.99% |
| % Institutions | 70.59% |
Historical Volatility
HV 10-Day
50.65%
HV 20-Day
71.31%
HV 30-Day
67.89%
HV 60-Day
75.21%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($9.00 target)
1
BuyLatest News
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company's oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) caused by infection with the parasite T. cruzi. Key findings from the two studies: In NHPs with naturally acquire.
Business Wire6/4/2026Neutral
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics we.
Business Wire5/21/2026Neutral
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2026. “This was an important quarter for AN2 as we announced an exciting new program in polycythemia vera that is planned to enter Phase 2 development in the third quarter of 2026. This pr.
Business Wire5/11/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026